US LABS Selects XIFIN To Improve Revenue Cycle Management

Combination of Technology and Services Key Selection Factors

June 10, 2003

US LABS, one the nation's fastest growing, privately held anatomic pathology laboratories, has selected XIFIN(TM) as the exclusive provider of financial systems and services for its billing and AR management.

"With our rapid growth, managing cash flow is critical," said Steve Pierce, CFO of US LABS. "XIFIN's combination of leading edge technology and on-going expert services was the clear choice in that, regardless of growth or changes in our business, they'll maximize our operational efficiency and bottom-line cash flow."

US LABS looks to improve revenue cycle management through the use of XIFIN's solution, which provides laboratories with all of the necessary resources and capabilities to successfully manage within today's complex reimbursement environment. At its core, XIFIN delivers workflow automation and complete IT infrastructure. Additionally, XIFIN's services continuously monitors, manages and provides access to all essential connectivity, transaction resources and service providers. This powerful combination translates into dramatic results, including; maximized cash flow, reduced compliance liability and overall lower staffing and operations costs.

"We're very pleased to be working with one of the leading pathology laboratories in the country," said Lale White, CEO of XIFIN. "Pathology has an unusual set of billing complexities which quickly overwhelm traditional billing software. US Labs will really showcase the capabilities of our offering."

About US LABS
Irvine-based US LABS is a national, diversified health care cancer diagnostic and genomics services company devoted to comprehensive, high quality, rapid response cancer testing. The company provides screening, diagnostic and prognostic cancer testing services to hospitals, physician offices and surgery centers. US LABS serves doctors and patients throughout the United States.